Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK
 

By selecting this, I agree to receive emails from celltelligence.com.


You will be granted access to your Celltelligence Library to view the full article after sign up.

Breyanzi Starts EMA Assessment in 2L LBCL (TI); Tecartus and Yescarta Absent from June's CHMP Agenda

Here is a brief preview of this blast: On Monday, June 20, the CHMP agenda for June was released. Of note, Breyanzi (BMS’s CD19 CAR-T) was listed as 'Start of Procedure' under 'Type II Variations: Extension of Indications' for 2L LBCL transplant-intended (TI) patients. Additionally, Tecartus (Gilead / Kite’s CD19 CAR-T) in r/r adult B-ALL and Yescarta (Gilead / Kite’s CD19 CAR-T) for 2L LBCL were absent from the CHMP agenda.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.